Top 5 Biotech Angel Investors in New Zealand

Last updated: Apr 2024 A list of 5 angel investors that invest in Biotech startups based in New zealand. We rank investors based on the number of investments they made in Biotech companies from New zealand. We update this investor list every month.

Top 5 Biotech Angel Investors in New Zealand

Investor	Biotech New Zealand investments
Paul Davidson	1
Melanie Melanie	1
David Ross	1
Marko Bogoievski	1
Serge van Dam	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Paul Davidson joined private equity group, West Coast Capital in 2005 following a successful career in corporate law in the UK, the US and Commonwealth of Independent States. As an active partner in West Coast Capital as well as providing legal counsel, Paul focusses on deal sourcing and transacting.Since joining the group, Paul has successfulyled the acquisition and delisting from the LSE of the UK's largest garden centre business, Wyevale as well as a series of acquisitions and disposals.Prior to joining West Coast Capital headed the corporate team of UK lawyers, McGrigors.In late 1994 Paul was seconded to an oil and gas company called JKX whose focus was on the former Soviet Union, primarily in Ukraine, Georgia and the Russian Federation. JKX listed on the London Stock Exchange in mid 1995 and at that time Paul joined the company as its Legal Director on a full time basis. During his time as Legal Director, Paul gained wide commercial experience as the company concluded a number of transactions throughout the former Soviet Union.

Investment focus

SaaS, FinTech, Privacy
Seed, Series A, Series B
Finland, New Zealand, United Kingdom

Portfolio highlights

Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand
TVSquared — With trusted, independent attribution and partnerships with DSPs, publishers, advertisers and MVPDs, TVSquared measures the effectiveness of TV advertising through an infinitely scalable platform for linear, addressable and OTT/CTV.
Ubisecure — Ubisecure B2B IAM, Legal Entity Identifiers LEI, IDaaS and hybrid identity management. European SSO, MFA, LEI made easy.

Investor

Investment focus

Biotechnology, Product Research
Seed
New Zealand

Portfolio highlights

Daisy Lab — Daisy Lab pioneers precision fermentation technology in New Zealand

David Ross

Investment focus

Biopharma, Biotechnology
Seed
New Zealand

Portfolio highlights

Helico — Helico is developing a proprietary computational platform for synthetic biology research using modelling tools and AI-based prediction algorithms. The long-term aim is to develop a seed bank of different drugs able to be licensed to grow medical supplies in confined greenhouses anywhere in the world.

Marko retired as CEO of Morrison & Co in 2021 after 13 years of leading the business. He continues to provide guidance for investments in telecommunications and digital infrastructure. His 30 year career has been in the infrastructure and technology sectors in a variety of senior finance, operational and sales roles in the United States and NewZealand. Prior to joining Morrison & Co in 2008, Marko was CFO of Telecom NZ, responsible for corporate finance, M&A and group strategy. Marko is Chair of Vodafone New Zealand.

Investment focus

Biotechnology, Manufacturing
Funding Round
New Zealand

Portfolio highlights

Pictor — Pictor is a biotechnology company develops, manufactures and market immunodiagnostic products.

Serge has a depth of experience in technology startups that is difficult to rival. As CMO of M-Com, Serge led the growth of M-Com from a four person mobile commerce development company to the world's most successful provider of mobile banking and payment solutions (in both licensed and SaaS categories). He has since held executive levelpositions and Directorships, including as Chair on four boards, of many successful B2B SaaS companies. He is also an avid investor.